Stuart A. Arbuckle - 30 Jun 2023 Form 4 Insider Report for ImmunoGen, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 30 Jun 2023
Net transaction value: +$13,115
SEC form: 4
Accepted by SEC: 05 Jul 2023, 17:54:27 UTC
Prior SEC filing: 23 Jun 2023
Next SEC filing: 02 Oct 2023
Source filing: View source filing
Reporting owner signature: /s/ Renee Lentini, Attorney-in-Fact

Filing notes and source

Key filing fact

Stuart A. Arbuckle filed Form 4 for ImmunoGen, Inc. on 05 Jul 2023.

Key facts

This page summarizes Stuart A. Arbuckle's Form 4 filing for ImmunoGen, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jul 2023, 17:54.

Change

Previous filing in this sequence was filed on 23 Jun 2023.
Current net transaction value: +$13,115.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMGN transaction

Common Stock

Award

Transaction value: $13,115
Shares: +695
Change %: +20%
Price: $18.87
Shares after: 4,112
Date: 30 Jun 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 for services performed for the quarter ended June 30, 2023.